Sumida Keiichi, Kwak Lucia, Grams Morgan E, Yamagata Kunihiro, Punjabi Naresh M, Kovesdy Csaba P, Coresh Josef, Matsushita Kunihiro
Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD; Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis, TN; Department of Nephrology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Am J Kidney Dis. 2017 Nov;70(5):675-685. doi: 10.1053/j.ajkd.2017.05.021. Epub 2017 Jul 26.
Reduced lung function is associated with clinical outcomes such as cardiovascular disease. However, little is known about its association with incident end-stage renal disease (ESRD) and chronic kidney disease (CKD).
Prospective cohort study.
SETTING & PARTICIPANTS: 14,946 participants aged 45 to 64 years at baseline (1987-1989) in the Atherosclerosis Risk in Communities (ARIC) Study (45.0% men and 25.2% black), with follow-up through 2012.
Race- and sex-specific quartiles of percent-predicted forced vital capacity (FVC) and the proportion of forced expiratory volume in 1 second of expiration to FVC (FEV/FVC) at baseline determined with spirometry.
Incident ESRD (defined here as renal replacement therapy or death due to CKD) as the primary outcome and incident CKD (defined here as ESRD, ≥25% decline in estimated glomerular filtration rate to a level <60mL/min/1.73m, or CKD-related hospitalizations/deaths) as the secondary outcome.
During a median follow-up of 23.6 years, 526 (3.5%) participants developed ESRD. After adjusting for potential confounders, the cause-specific HR of incident ESRD for the lowest (vs highest) quartile was 1.72 (95% CI, 1.31-2.26) for percent-predicted FVC and 1.33 (95% CI, 1.03-1.73) for FEV/FVC. Compared to a high-normal lung function pattern, a mixed pattern (ie, percent-predicted FVC<80% and FEV/FVC<70%; 3.4% of participants) demonstrated the highest adjusted cause-specific HR of ESRD at 2.28 (95% CI, 1.50-3.45), followed by the restrictive pattern (ie, percent-predicted FVC<80% and FEV/FVC≥70%; 4.8% of participants) at 2.03 (95% CI, 1.47-2.81), obstructive pattern (ie, percent-predicted FVC≥80% and FEV/FVC<70%; 18.9% of participants) at 1.47 (95% CI, 1.09-1.99), and low-normal pattern (ie, percent-predicted FVC 80%-<100% and FEV/FVC≥70%, or percent-predicted FVC≥80% and FEV/FVC 70%-<75%; 44.3% of participants) at 1.21 (95% CI, 0.94-1.55). Similar associations were seen with incident CKD.
Limited number of participants with moderate/severe lung dysfunction and spirometry only at baseline.
Reduced lung function, particularly lower percent-predicted FVC, is independently associated with CKD progression. Our findings suggest a potential pathophysiologic contribution of reduced lung function to the development of CKD and a need for monitoring kidney function in persons with reduced lung function.
肺功能下降与心血管疾病等临床结局相关。然而,关于其与新发终末期肾病(ESRD)和慢性肾脏病(CKD)的关联知之甚少。
前瞻性队列研究。
社区动脉粥样硬化风险(ARIC)研究中1987 - 1989年基线时年龄在45至64岁的14,946名参与者(男性占45.0%,黑人占25.2%),随访至2012年。
通过肺量计测定的基线时按种族和性别分层的预测用力肺活量(FVC)百分比四分位数以及第1秒用力呼气量与FVC的比例(FEV/FVC)。
将新发ESRD(此处定义为肾脏替代治疗或因CKD死亡)作为主要结局,新发CKD(此处定义为ESRD、估计肾小球滤过率下降≥25%至<60 mL/min/1.73m²水平或与CKD相关的住院/死亡)作为次要结局。
在中位随访23.6年期间,526名(3.5%)参与者发生了ESRD。在调整潜在混杂因素后,预测FVC百分比最低(与最高)四分位数的新发ESRD病因特异性风险比为1.72(95%置信区间,1.31 - 2.26),FEV/FVC为1.33(95%置信区间,1.03 - 1.73)。与高正常肺功能模式相比,混合模式(即预测FVC百分比<80%且FEV/FVC<70%;3.4%的参与者)显示ESRD调整后的病因特异性风险比最高,为2.28(95%置信区间,1.50 - 3.45),其次是限制性模式(即预测FVC百分比<80%且FEV/FVC≥70%;4.8%的参与者),为2.03(95%置信区间,1.47 - 2.81),阻塞性模式(即预测FVC百分比≥80%且FEV/FVC<70%;18.9%的参与者)为1.47(95%置信区间,1.09 - 1.99),低正常模式(即预测FVC 80% - <100%且FEV/FVC≥70%,或预测FVC百分比≥80%且FEV/FVC 70% - <75%;44.3%的参与者)为1.21(95%置信区间,0.94 - 1.55)。新发CKD也观察到类似关联。
中度/重度肺功能障碍参与者数量有限且仅在基线时进行肺量计测定。
肺功能下降,尤其是预测FVC百分比降低,与CKD进展独立相关。我们的研究结果提示肺功能下降对CKD发生发展可能存在病理生理贡献,且有必要对肺功能下降者的肾功能进行监测。